$15.54
0.91%
Nasdaq, Jan 02, 10:02 pm CET
ISIN
US45249V1070
Symbol
ELVN

Imara Inc Stock price

$15.54
-5.02 24.42% 1M
-5.10 24.71% 6M
+0.14 0.91% YTD
-8.36 34.98% 1Y
-0.82 5.01% 3Y
-80.38 83.80% 5Y
-44.46 74.10% 10Y
-44.46 74.10% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.14 0.91%
ISIN
US45249V1070
Symbol
ELVN
Industry

Key metrics

Basic
Market capitalization
$922.3m
Enterprise Value
$444.7m
Net debt
positive
Cash
$477.6m
Shares outstanding
59.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 108,544.6
EV/Sales
- | 52,337.4
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
95.1%
Return on Equity
-28.7%
ROCE
-23.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $8.5k
EBITDA
$-112.0m | $-116.4m
EBIT
$-112.3m | $-114.6m
Net Income
$-97.2m | $-104.3m
Free Cash Flow
$-71.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-11.5% | -11.6%
EBIT
-11.5% | -9.6%
Net Income
-14.2% | -17.2%
Free Cash Flow
-4.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -1,369,423.8%
EBIT
-
Net
- | -1,227,806.0%
Free Cash Flow
-
More
EPS
$-1.6
FCF per Share
$-1.2
Short interest
19.5%
Employees
62
Rev per Employee
$0.0
Show more

Is Imara Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Imara Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Imara Inc forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Imara Inc forecast:

Buy
94%
Hold
6%

Financial data from Imara Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 27 27
20% 20%
-
- Research and Development Expense 85 85
9% 9%
-
-112 -112
12% 12%
-
- Depreciation and Amortization 0.29 0.29
9% 9%
-
EBIT (Operating Income) EBIT -112 -112
11% 11%
-
Net Profit -97 -97
14% 14%
-

In millions USD.

Don't miss a Thing! We will send you all news about Imara Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Imara Inc Stock News

Neutral
PRNewsWire
23 days ago
BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven"), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that on December 11, 2025, Enliven granted an inducement stock option to purchase 875,000 shares of Enliven's common stock to Richard Fair, Enliven's President and...
Neutral
PRNewsWire
23 days ago
Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer Co-Founder Sam Kintz will assume a new position as Head of Pipeline BOULDER, Colo. , Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery ...
Positive
Seeking Alpha
about 2 months ago
Enliven Therapeutics remains overvalued relative to its early-stage pipeline progress and current financials. ELVN-001 shows promising safety and efficacy signals in heavily pretreated CML patients, with a pivotal phase 3 trial planned for 2026. ELVN is well-capitalized, with over four years of cash runway, but faces a competitive and relatively small CML market.
More Imara Inc News

Company Profile

Imara, Inc. engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a highly selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA.

Head office United States
CEO Samuel Kintz
Employees 62
Founded 2019
Website www.enliventherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today